Posts

Drugmakers with White House MFN Deals Claim Exemption from Proposed Medicare Pricing Tests

on

Biogen Issues Statement Mourning Co-Founder Charles Weissmann's Passing

on

Novo Nordisk Wins FDA Approval for First Oral GLP-1 Wegovy Pill in Obesity Treatment

on

Neurocrine's VMAT2 Inhibitor Valbenazine Fails in Phase 3 Trial for Dyskinetic Cerebral Palsy

on

Patient Dies from Thrombotic Stroke in Pfizer's Hympavzi Hemophilia Trial After Minor Surgery

on

Gilead's $35M Herpes Deal with Assembly Biosciences and Recent FDA Approvals

on

Breakthrough Real-World Evidence Powering Blood Cancer Research in 2025

on

Aktis Oncology Files for IPO to Fund Lilly-Partnered Radiopharma Pipeline

on

Shionogi Announces $2.5 Billion Acquisition of ALS Drug Radicava from Tanabe Pharma

on

FDA Approves Novo Nordisk's Wegovy Pill as First Oral GLP-1 for Weight Management

on

Spotlight On: Five Key FDA Approvals of 2025

on

Brainomix AI Reveals Hidden Efficacy of ARG-007 in Severe Stroke Patients

on

AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio's Pan-KRAS Inhibitor JAB-23E73

on

Bayer's Finerenone Approved in Japan for Chronic Heart Failure Treatment

on

BioMarin Announces $4.8 Billion Acquisition of Amicus Therapeutics for Rare Disease Portfolio Expansion

on

FDA Approves Cytokinetics' Myqorzo for Obstructive Hypertrophic Cardiomyopathy, Positioning It Against BMS's Camzyos

on

White House unveils nine new “most-favored-nation” drug pricing deals

on

FDA places partial clinical hold on Merck and Daiichi Sankyo’s I-DXd lung cancer trial after interstitial lung disease deaths

on

Recent Biotech News: Altimmune's Pemvidutide Advances in MASH, Emerging China Obesity Players, and Ipsen Phase 2 Setback

on

Insmed Delivers Rare Disappointment as Brinsupri Flops in Mid-Stage Rhinosinusitis Study

on

Moderna Lands CEPI as New Backer for Its Pandemic Flu (H5 Bird Flu) Program

on

Endpoints News Topics at 2026 JPM Healthcare Conference: CEOs, Investors, China, and Beyond

on

Ipsen's Fidrisertib Fails Primary Endpoint in Pivotal Phase II FALKON Trial for Rare Bone Disease FOP

on

Coloplast announces changes to Executive Leadership Team

on

Quantori and Expert Systems Partner to Accelerate Drug Discovery with Foundational Predictive AI Models

on

Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study

on

GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics

on

Exclusive: Compounding giant Empower Pharmacy cuts hundreds of staff, stops New Jersey operations

on

No public results for “Take the Biopharma Sentiment Index” Q1 2026 yet

on

Biopharma’s Winners and Losers of 2025 – Endpoints News recap

on

Padcev-Keytruda Combination Succeeds Again in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

on

Jim Lang Appointed to the Board of Directors of Halozyme Therapeutics

on

Models are out, molecules are in as AI drug startups sprint to the clinic

on

The 5 Most Painful Clinical Trial Failures of 2025

on

FDA Commissioner Makary Addresses COVID-19 Vaccine Safety Concerns Amid Internal Debates and Investigations

on

Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

on

Berkeley startup raises $106.5M for all‑RNA ‘jumping gene’ therapies

on

Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites

on

Nektar Digs Into Mid-Stage Data To Establish Alopecia Efficacy of Rezpeg

on

RTW-backed startup Yarrow Bioscience signs autoimmune antibody deal with China’s GenSci

on

Ambros Therapeutics launches with $125M to develop non-opioid chronic pain drug neridronate

on

GSK wins FDA approval for ultra-long-acting asthma drug Exdensur (depemokimab)

on